Easterly Government Properties (DEA)
(Delayed Data from NYSE)
$13.60 USD
-0.15 (-1.09%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $13.60 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
C Value D Growth C Momentum D VGM
Price, Consensus and EPS Surprise
DEA 13.60 -0.15(-1.09%)
Will DEA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for DEA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for DEA
Easterly Government Expands Portfolio With Strategic Acquisitions
Easterly Government Properties (DEA) Reports Q2 Earnings: What Key Metrics Have to Say
DEA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Easterly Government Properties (DEA) Q2 FFO Match Estimates
Welltower (WELL) Tops Q2 FFO Estimates
Easterly Government Properties (DEA) Just Flashed Golden Cross Signal: Do You Buy?
Other News for DEA
Easterly Government Properties CEO Adds President Role
Meet The Man Serving A 40-Year Sentence For Non-Violent Cannabis Charges, Awaiting Pardon From Biden
Cannabis Experts Say Weed Reform Is A Race Against Time, Is The DEA Delaying Biden's Rescheduling Proposal?
Easterly Government Properties: 8% Dividend Yield And Increased Investment Activity; Potential Attractive Opportunity
EXCLUSIVE: DEA Stalling Hinders Critical Clinical Trials For Debilitating Conditions, Says MMJ BioPharma CEO